.Pharmacolibrary.Drugs.ATC.J.J02AX08 .Pharmacolibrary.Drugs.ATC.J.J02AX08| name: | RezafunginAcetate |
| ATC code: | J02AX08 | route: | intravenous |
| n-compartments | 2 |
Rezafungin acetate is an echinocandin antifungal agent indicated for the treatment of candidemia and invasive candidiasis. It acts by inhibiting the synthesis of β-(1,3)-D-glucan, an essential component of the fungal cell wall. Rezafungin was approved by the FDA in 2023 for clinical use in adults.
Pharmacokinetic parameters reported in adult healthy volunteers and patients with candidemia or invasive candidiasis after intravenous infusion.